欧雷强先生是百济神州创始人、董事长兼首席执行官。自2010年起他也担任董事会成员。此前,欧雷强先生于2005年至2009年担任医药研发外包企业保诺科技公司的总裁和首席执行官,该公司于2010年被医药产品开发公司(Pharmaceutical Product Development Inc.)收购。自2002年至2004年,欧雷强先生担任生物医药企业Galenea公司的首席执行官,该公司创立于麻省理工大学(Massachusetts Institute of Technology),专注研发中枢神经系统疾病的创新疗法。自1997年至2002年,欧雷强先生创办Telephia公司并担任总裁,该公司于2007年被尼尔森公司收购。1997年至1998年,欧雷强先生在专注肿瘤领域的生物医药企业Genta公司(纳斯达克代码:GNTA)担任联席首席执行官一职。欧雷强先生的职业生涯始于美国麦肯锡公司商业咨询顾问。欧雷强先生拥有斯坦福大学工商管理硕士学位及麻省理工大学学士学位。

John V. Oyler is our Chairman and Co-Founder, and has served as our Chief Executive Officer and a member of our Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.